Skip to main content
PMC home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2004 Apr 7;5(2):60–68. doi: 10.1208/pt050232

Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model

R B Umamaheshwari 1, Suman Ramteke 1, Narendra Kumar Jain 1,✉
PMCID: PMC2750467  PMID: 15760090

Abstract

The purpose of the present study was to design mucoadhesive gliadin nanoparticles (GNP) containing amoxicillin and to evaluate their effectiveness in eradicating Helicobacter pylori. GNP-bearing amoxicillin (AGNP) was prepared by desolvation method. The effect of process variables such as gliadin concentration and initial drug loading on particle size, shape, percent payload, percent entrapment efficiency, in vitro release profile, and mucoadhesive property of GNP was assessed. Rhodamine isothiocyanate-entrapped GNP formulations were prepared to evaluate their in vivo gastric mucoadhesive property in albino rats. With increasing gliadin concentration, the mucoadhesive property of GNP increased. Typically, the maximum amount of nanoparticles remaining was 82±4%, which represented a stronger mucoadhesive propensity and specificity of GNP toward the stomach. In vitro antimicrobial activity of AGNP was evaluated by growth inhibition studies on an isolated H pylori strain. The time required for complete eradication was higher in AGNP than in amoxicillin because of the controlled drug delivery of amoxicillin from AGNP. In vivo clearance of H pylori following oral administration of AGNP to infected Mongolian gerbils was examined. Amoxicillin and AGNP both showed anti-H pylori effects in this experimental model of infection, but the required dose for complete eradication was less in AGNP than in amoxicillin. In conclusion, AGNP eradicated H pylori from the gastrointestinal tract more effectively than amoxicillin because of the prolonged gastrointestinal residence time attributed to mucoadhesion. A dosage form containing mucoadhesive nanoparticles bearing a potential antibiotic should be useful for the complete eradication of H pylori.

Keywords: gliadin, mucoadhesion, nanoparticles, H pylori, amoxicillin

Full Text

The Full Text of this article is available as a PDF (206.8 KB).

References

  • 1.Warren JR, Marshall B. Unified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;321:1273–1275. doi: 10.1016/S0140-6736(83)92719-8. [DOI] [PubMed] [Google Scholar]
  • 2.Megrand F, Lamouliatte H. Helicobacter pylori and duodenal ulcers. Dig Dis Sci. 1992;37:769–772. doi: 10.1007/BF01296437. [DOI] [PubMed] [Google Scholar]
  • 3.Forman D, Webb P, Parsonnet J. H. pylori and gastric cancer. Lancet. 1994;343:243–244. doi: 10.1016/S0140-6736(94)91034-0. [DOI] [PubMed] [Google Scholar]
  • 4.El-Shoura SM. Helicobacter pylori, I: ultrastructural sequences of adherence, attachment, and penetration into the gastric mucosa. Ultrastruct Pathol. 1995;19:323–333. doi: 10.3109/01913129509064237. [DOI] [PubMed] [Google Scholar]
  • 5.Engstrand L, Graham DY, Scheynius A, Genta RM, El-zaatari F. Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol. 1997;108:504–509. doi: 10.1093/ajcp/108.5.504. [DOI] [PubMed] [Google Scholar]
  • 6.Buckholm G, Tannaes T, Nedenskov P, et al. Colony variation of Helicobacter pylori: pathogenic potential is correlated to cell wall lipid composition. Scand J Gastroenterol. 1997;32:445–454. doi: 10.3109/00365529709025079. [DOI] [PubMed] [Google Scholar]
  • 7.Evans DG, Evans DJ, Graham DY. Adherence and internalization of Helicobacter pylori by HEp-2 cells. Gastroenterology. 1992;102:1557–1567. doi: 10.1016/0016-5085(92)91714-f. [DOI] [PubMed] [Google Scholar]
  • 8.Kwok T, Backert S, Schwarz H, Berger J, Meyer TF. Specific entry of Helicobacter pylori into cultured gastric epithelial cells via a zipper-like mechanism. Infect Immun. 2002;70:2108–2120. doi: 10.1128/IAI.70.4.2108-2120.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Nagahara N, Akiyama Y, Tada M, Nakao M, Kitano M, Ogawa Y. Mucoadhesive microspheres containing amoxycillin for clearance of Helicobacter pylori. Antimicrob Agents Chemother. 1998;42:2492–2494. doi: 10.1128/aac.42.10.2492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hejazi R, Amiji M. Stomach-specific anti-H. pylori therapy, I: preparation and characterization of tetracycline-loaded chitosan microspheres. Int J Pharm. 2002;235:87–94. doi: 10.1016/S0378-5173(01)00985-1. [DOI] [PubMed] [Google Scholar]
  • 11.Umamaheshwari RB, Jain S, Jain NK. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv. 2003;10:151–160. doi: 10.1080/713840399. [DOI] [PubMed] [Google Scholar]
  • 12.Umamaheshwari RB, Jain S, Tripathi PK, Agrawal GP, Jain NK. Floating-bioadhesive microspheres containing acetohydroxamic acid for the clearance of Helicobacter pylori. Drug Deliv. 2002;9:221–233. doi: 10.1080/10717540260397837. [DOI] [PubMed] [Google Scholar]
  • 13.Ezpeleta I, Irache JM, Stainmesse S, Chabenat C, Popineau Y, Orecchionic AM. Preparation of Ulex europaeus lectin-gliadin nanoparticles conjugates and their interaction with gastrointestinal mucus. Int J Pharm. 1999;191:25–32. doi: 10.1016/S0378-5173(99)00232-X. [DOI] [PubMed] [Google Scholar]
  • 14.Arangoa MA, Campanero MA, Renedo MJ, Ponchel G, Irache JM. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res. 2001;18:1521–1527. doi: 10.1023/A:1013018111829. [DOI] [PubMed] [Google Scholar]
  • 15.Arangoa MA, Ponchel G, Orecchioni AM, Renedo MJ, Duchene D, Irache JM. Bioadhesive potential of gliadin nanoparticulate systems. Eur J Pharm Sci. 2000;11:333–341. doi: 10.1016/S0928-0987(00)00121-4. [DOI] [PubMed] [Google Scholar]
  • 16.Fontana G, Licciardi M, Mansueto S, Schilaci S, Giammona G. Amoxycillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials. 2001;22:2857–2865. doi: 10.1016/S0142-9612(01)00030-8. [DOI] [PubMed] [Google Scholar]
  • 17.Arangoa MA, Campanero MA, Popineau Y, Hirai S, Toguchi H. Evaluation and characterization of gliadin nanoparticles and isolates by reversed phase HPLC. J Cereal Sci. 2000;31:223–228. doi: 10.1006/jcrs.1999.0299. [DOI] [Google Scholar]
  • 18.Wang J, Tauch Y, Deguchi Y, Morimoto K, Tabata Y, Ikada Y. Positively charged gelatin microspheres as gastric mucoadhesive drug delivery system for clearance of H. pylori. Drug Deliv. 2000;7:237–243. doi: 10.1080/107175400455173. [DOI] [PubMed] [Google Scholar]
  • 19.Akiyama Y, Nagahara N, Tashihara T, Morimoto K, Tabata Y, Ikada Y. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm Res. 1995;12:397–405. doi: 10.1023/A:1016208703380. [DOI] [PubMed] [Google Scholar]
  • 20.Ikeno T, Ota H, Sngiyama A. Helicobacter pylori-induced chronic active gastritis, intestinal metaplasia and gastric ulcer in Mongolian gerbils. Am J Pathol. 1999;154:951–960. doi: 10.1016/S0002-9440(10)65343-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Shah S, Qaqish R, Patel V, Amiji M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharmacol. 1999;51:667–672. doi: 10.1211/0022357991772952. [DOI] [PubMed] [Google Scholar]
  • 22.Berry V, Jennings K, Woodnutt G. Bactericidal and morphological effects of amoxycillin on Helicobacter pylori. Antimicrob Agents Chemother. 1995;39:1859–1861. doi: 10.1128/aac.39.8.1859. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES